Compare ARBEW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARBEW | ERNAW |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Israel | United States |
| Employees | 145 | 5 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | ARBEW | ERNAW |
|---|---|---|
| Price | $0.05 | $0.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 34.4K | 3.1K |
| Earning Date | 03-05-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $768,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.03 | $0.02 |
| 52 Week High | $0.50 | $0.11 |
| Indicator | ARBEW | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 42.99 |
| Support Level | $0.04 | $0.02 |
| Resistance Level | $0.08 | $0.06 |
| Average True Range (ATR) | 0.01 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 23.75 | 4.87 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles, as well as for non-automotive uses. Geographically, the company generates maximum revenue from Sweden, and the rest from China, Hong Kong, the USA, Germany, Israel, and other markets.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.